# Levetiracetam in the Treatment of Neuroleptic-induced Tardive Dyskinesia

> **NCT00175955** · PHASE2 · COMPLETED · sponsor: **UCB Pharma** · enrollment: 70 (—)

## Conditions studied

- Dyskinesia, Medication-induced

## Interventions

- **DRUG:** Levetiracetam

## Key facts

- **NCT ID:** NCT00175955
- **Lead sponsor:** UCB Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05
- **Primary completion:** 2005-12
- **Final completion:** 2005-12
- **Target enrollment:** 70 (—)
- **Last updated:** 2013-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00175955

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00175955, "Levetiracetam in the Treatment of Neuroleptic-induced Tardive Dyskinesia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00175955. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*